Tim of the Oak
Well-Known Member
- Joined
- 29 Dec 2012
- Messages
- 20,845
It might be from the data but the alleged lack of over 55s seemed to be a rumour (based on how I read the article). If over 55s haven’t been included in the research then Oxford / AZ won’t get MHRA approval. IIRC Oxford / AZ claimed in the peer reviewed tier 2 testing found the planned vaccine was effective for older people but I don’t know the age breakdown of the volunteers.That's irrelevant. Not gonna bring pointless nationalism into it. Genuinely, it's a concern and not speculation. It's from their data. They can't confidently say it's safe for over 55s if there has been barely any given it.
The article might be spot on and the points about the Oxford / AZ research being less transparent and more complicated could well be true. That said, I question its independence because why doesn’t the writer clearly
make the point that Oxford / AZ couldn’t rely on completing the trial in the States because the FDA had blocked progress after the adverse incident. The writer mentions the adverse incident and seems to expect AZ to just hang about until the FDA gave clearance, which was an indefinite timescale.
Last edited: